Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 5/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | HSD17B3 | P37058 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 1/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Androsterone SCHEMBL2383099 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL16258913 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Etiocholanolone SCHEMBL148334 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL15369415 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL12968676 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL23031469 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL16385946 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL8253266 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL21114416 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL13641972 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | claimed |
| EP-2938654-B1 | MOLECULARLY IMPRINTED POLYMER OF SOL-GEL TYPE FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | OREAL (FR) | 2016-08-24 | — | — | EP | claimed |
| US-20160038536-A1 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION | SAPNA LIFE SCIENCES CORPORATION (CA) | 2016-02-11 | — | — | US | claimed |
| US-20150342868-A1 | MOLECULARLY IMPRINTED POLYMER OF SOL-GEL TYPE FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | LOREAL (FR) | 2015-12-03 | — | — | US | claimed |
| US-20150320667-A1 | MOLECULARLY IMPRINTED POLYMER FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | L'OREAL (FR) | 2015-11-12 | — | — | US | claimed |
| EP-2938402-A1 | MOLECULARLY IMPRINTED POLYMER FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | L'OREAL (FR) | 2015-11-04 | — | — | EP | claimed |
| EP-2938654-A1 | MOLECULARLY IMPRINTED POLYMER OF SOL-GEL TYPE FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | L'OREAL (FR) | 2015-11-04 | — | — | EP | claimed |
| WO-2014108808-A2 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION | HENRY JAMES LORNE (CA) | 2014-07-17 | — | — | WO | claimed |
| WO-2014108809-A2 | MULTIPLE-COMPONENT PHARMACEUTICAL FORMULATIONS AND METHODS FOR THEIR USE IN TREATING NEUROPATHOLOGY AND NEURODEGENERATION CAUSED BY TRAUMATIC INJURY | HENRY JAMES LORNE (CA) | 2014-07-17 | — | — | WO | claimed |
| WO-2014107794-A1 | FORMULATIONS AND METHODS FOR THEIR USE IN TREATMENT OF NEUROPATHOLOGY AND NEURODEGENERATION AS A RESULT OF TRAUMATIC INJURY | SAPNA LIFE SCIENCES CORP. (CA) | 2014-07-17 | — | — | WO | claimed |
| WO-2000056757-A1 | IMMUNOMODULATORY STEROIDS, IN PARTICULAR THE HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | claimed |
| WO-2000032176-A2 | USE OF 17-KETOSTEROIDS FOR THE TREATMENT OF TOXOPLASMOSIS AND CRYPTOSPORIDOSIS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2000-06-08 | — | — | WO | claimed |
| WO-2000032201-A2 | USE OF 17-KETOSTEROIDS FOR THE TREATMENT OF MALARIA AND TRYPANOSOMIASIS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2000-06-08 | — | — | WO | claimed |
| EP-0659072-A1 | PHARMACEUTICAL EMULSIONS CONTAINING BIOACTIVE STEROIDS | Pharmacia AB (SE) | 1995-06-28 | — | — | EP | claimed |
| WO-1995001162-A1 | PHARMACEUTICAL EMULSIONS CONTAINING BIOACTIVE STEROIDS | PHARMACIA AB (SE) | 1995-01-12 | — | — | WO | claimed |
| US-4897390-A | 3-METHYLANDROSTAN-17-ONE; CONCURRENT SUPPRESSION OF CALORIC INTAKE AND INCREASE OF CALORIC EXPENDITURE | HUMANETICS CORPORATION | 1990-01-30 | — | — | US | claimed |
| EP-0148436-B1 | TREATMENT OF DIABETES AND OTHER SYMPTOMS OF HYPERCORTICOIDISM USING A SYNERGISTIC COMBINATION OF ETIOCHOLANOLONES AND ESTROGEN | The Jackson Laboratory (US) | 1988-10-12 | — | — | EP | claimed |
| EP-0149220-A2 | Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones | The Jackson Laboratory (US) | 1985-07-24 | — | — | EP | claimed |
| EP-0148436-A1 | Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen | The Jackson Laboratory (US) | 1985-07-17 | — | — | EP | claimed |
| US-4507289-A | Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen | PROGENICS, INC. (US) | 1985-03-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | G6PD 4611/4885GPBAR1 672/4885LMNA 3666/4885 |
| US-20150342868-A1 | MOLECULARLY IMPRINTED POLYMER OF SOL-GEL TYPE FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | TAS2R30, TAS1R1, TAS2R10 | G6PD 3970/4885GPBAR1 2938/4885LMNA 4639/4885 |
| US-20150320667-A1 | MOLECULARLY IMPRINTED POLYMER FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | OR10J3, OR51E2, MSMO1 | G6PD 3301/4885GPBAR1 2160/4885LMNA 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.